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SUMMARY 
National Surveillance of Dialysis-Associated Diseases in the United States, 1997 
! See the Summary Table on the following page. 
! This survey was performed yearly during 1982-1997 by the Centers for Disease Control 
and Prevention (CDC) and the Health Care Financing Administration (HCFA). 
! This survey was NOT performed in 1998. We are currently in the process of revising 
the survey which will be performed again at the end of 1999. 
! Hepatitis B vaccine use.  For 1997, the survey question was changed to include vaccine 
receipt among patients treated, or staff members working, during the last week of the 
year. Previous surveys had included patients and staff members from throughout the year. 
In part because of this change in methodology, the percent vaccinated increased to 87% 
among staff and 47% among patients. 
! Hepatitis B vaccine efficacy. A case-control study based on data from the 1995 survey 
showed that hepatitis B vaccine was 70% effective in preventing newly-acquired hepatitis 
B virus infection in chronic hemodialysis patients (Am J Kidney Disease, 1999;32:1-6). 
! Hepatitis C virus. In 1997, routine testing for antibody to hepatitis C virus (anti-HCV) 
was performed on staff at 25% of centers and on patients at 48% of centers. At centers 
testing, anti-HCV was found in 1.6% of staff and 9.3% of patients. 
! Vascular access. During 1995-1997, the percentage of patients dialyzed through central 
catheters increased from 13% to 17%. This trend is worrisome since infections and 
antimicrobial use are higher in patients dialyzed through catheters. 
! Vancomycin use. The median percentage of patients reported to have received 
vancomycin during December decreased from 5.6% in 1995 to 4.5% in 1998. We hope 
that this is due to efforts of personnel at many dialysis centers to avoid unnecessary 
vancomycin use, and that such efforts will be continued and/or expanded. 
! Vancomycin-resistant enterococcus (VRE). The percent of centers reporting one or 
more patients infected or colonized with VRE increased from 11.5% in 1995 to 29.8% in 
1996. This most likely represents increased recognition, rather than an actual increase, of 
VRE. 
! Voluntary surveillance for bacteremia and vascular access infections.  Because of the 
importance of these issues, CDC has developed a voluntary surveillance system which will 
be available for general use in March 1999. See Appendix V or contact Elaine Miller at 





National Surveillance of Dialysis-Associated Diseases in the United States, 1995-1997
 
Category Unit of Measurement Year 
1995 1996 1997 
Centers responding to survey number of centers 2,647 2,808 3,077 
Patient:staff ratio median 4.2 3.9 4.1 
Reuse dialyzers % of centers 77 81 82 
Total staff, all centers number of staff 54,194 59,882 63,054 
Hepatitis B vaccination, staff % of staff 82 82 87* 
Test staff for anti-HCV % of centers 16 20 25 
Anti-HCV prevalence, staff % of staff 2.0 1.3 1.6 
Total patients, all centers number of patients 224,954 228,527 253,001 
Vascular access
 Arteriovenous graft 
% of patients 
65 63 60
 Arteriovenous fistula 22 22 23
 Central catheter 13 15 17 
Hepatitis B vaccination, patients % of patients 35 36 47* 
Test patients for anti-HCV % of centers 39 44 48 
Anti-HCV prevalence, patients % of patients 10.4 10.1 9.3 
HIV infection % of patients 1.4 1.4 1.3 
AIDS % of patients 0.7 0.7 0.6 
Vancomycin use, December % of patients, median 5.6 5.1 4.5 
Vancomycin-resistant enterococcus (VRE) 
% of centers 
with $ 1 patient 
11.5 21.3 29.8 
Methicillin-resistant 
Staphylococcus aureas (MRSA) 40 48 56 
Active tuberculosis 7.9 7.4 6.8
 Anti-HCV denotes antibody to hepatitis C virus 
* Note differences in methodology in 1997 as explained in the Summary 
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INTRODUCTION 
The Centers for Disease Control and Prevention (CDC) has been conducting surveillance 
of hemodialysis-associated hepatitis since the early 1970s (1), when CDC reported that the 
incidence of HBV infection among patients and staff during 1972-1974 had increased by more 
than 100% to 6.2% and 5.2%, respectively. These early surveys had only a 50% to 65% 
response rate of centers listed by the National Dialysis Registry. In an effort to obtain a higher 
response rate, and thus more complete information, CDC initiated a cooperative program with 
the Health Care Financing Administration (HCFA) in 1976 that provided for a questionnaire 
from CDC to be included in HCFA's annual facility survey. As a result of this collaboration, the 
response rates to the CDC questionnaire now exceed 90%.
 Since collaboration with HCFA was begun, the CDC survey has been performed for 
calendar years 1976, 1980, and 1982 to 1997 (2-12). Other hemodialysis-associated diseases 
and practices not related to hepatitis have been included over the years, and the questionnaire is 
continually updated to collect data about hemodialysis practices and hemodialysis-associated 
diseases of current interest and importance. The objectives of this yearly survey are to (a) 
determine the frequency with which certain hemodialysis practices, including measures designed 
to prevent disease, are used, (b) determine the frequency of hemodialysis-associated 
complications and diseases, and (c) use this information to suggest further measures to prevent 
complications and disease in hemodialysis patients and staff. 
METHODS 
In conjunction with the annual facility survey performed by HCFA for calendar year 
1997, CDC distributed a questionnaire (see Appendix I) by mail to all 3,228 chronic 
hemodialysis centers licensed by HCFA. All responses were reviewed, and approximately 20% 
of centers that responded provided inaccurate or inconsistent responses and were contacted for 
clarification of responses. The survey covered: 
a.	 hemodialysis practices, such as the types of dialysate (acetate vs bicarbonate) 
used, use of high flux (dialyzer UFR $20) and high efficiency (dialyzer UFR 
10-19) dialysis, reuse of disposable dialyzers, type of vascular access, procedures 
for cleaning and disinfection of dialysis equipment, and management of patients 
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positive for hepatitis B surface antigen (HBsAg). 
b. the results of testing patients and staff for HBsAg, antibody to HBsAg (anti-HBs), 
and antibody to hepatitis C virus (anti-HCV). 
c. the number of patients who received vancomycin in December 1997, and whether 
$1 patient with vancomycin-resistant enterococcus (VRE), methicillin-resistant 
Staphylococcus aureus (MRSA), or active tuberculosis requiring treatment was 
dialyzed during 1997. 
d. the occurrence of other hemodialysis-associated complications and diseases such 
as hepatitis C/non-A non-B hepatitis, vascular access infections, bacteremia, 
pyrogenic reactions and new dialyzer syndrome. 
e. the number of patients with human immunodeficiency virus (HIV) infection and 
policies for testing patients for HIV. 
The incidence of hepatitis B virus (HBV) infection was defined as the percentage of all 
patients or staff present in the facility in 1997 who became positive for HBsAg during 1997. 
The prevalence rates of chronic HBV infection and immunity were defined as the percentage of 
all patients or staff present in the facility during the last week of December 1997 who were 
positive for HBsAg or anti-HBs, respectively. All patients or staff (i.e., regardless of their 
susceptibility to HBV infection) were included in calculations of the incidence and prevalence of 
HBV infection. Among groups of dialysis centers, the median percent of patients receiving 
vancomycin in December 1997 was calculated by weighting each dialysis center by the number 
of patients treated. 
Information on dialysis center location and ownership was obtained from a data tape 
supplied by HCFA. The results of the 1997 survey were compared to results from previous 
surveys. 
Proportions were compared with the chi square or Fisher's exact test; when adjustment 
for confounding variables was required, the Mantel-Haenszel test or logistic regression was used. 
All p-values were two-tailed; a p-value of <0.05 was considered statistically significant. 
RESULTS AND DISCUSSION 
Questionnaires were returned by 3,077 (95%) of 3,228 centers. These 3,077 centers 
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represented 253,001 patients and 63,054 staff members. During 1985-1997, the median number 
of patients per center increased from 50 to 71, the median number of staff per center increased 
from 15 to 17, and the median patient to staff ratio increased from 3.4 to 4.1 (Table 1). During 
the same period, the proportion of freestanding (i.e., located outside the hospital) centers 
increased from 56% to 77%, and the proportion of centers operating for profit increased from 
46% to 70% (Table 2). 
In 1997, 84% of centers used a record-keeping system to track dialysis-associated 
diseases in patients. Among those using a formal system, 14% used a computer database, 45% 
used written records other than patient charts, and 41% used both computer and written records. 
Of centers using a formal record-keeping system, 82% included HBsAg, 78% vascular access 
infections, 72% pyrogenic reactions, 74% anti-HBs, 70% bacteremia, and 51% anti-HCV. 
Dialysis Practices and Reuse of Disposables 
In 1997, 13% of centers reported using only conventional dialyzer membranes, of which 
most were either cuprophan or cellulose acetate, and 87% reported using high flux dialyzer 
membranes, of which most were polysulfone, on at least some of their patients (Table 3). 
In 1997, 63% of centers reported treating some patients by high flux dialysis, an increase 
from 15% in 1987, and 70% reported treating some patients by high efficiency dialysis (Table 
4). During the same period, increases in numbers of patients treated with high flux and high 
efficiency dialysis also occurred (Table 4). 
During 1990-1997, all centers treated water used for dialysis; in comparison, 5% of 
centers reported using untreated water for dialysis in 1980 (Table 5). The use of reverse osmosis 
(RO) for treatment of water, either alone or with other modalities such as deionization (DI), 
increased from 26% in 1980 to 97% in 1997. 
During 1976-1986, the percentage of centers that reported reuse of disposable dialyzers 
increased from 18% to 82% (Table 6). Among centers that reused disposable dialyzers, the 
average (median 15) and maximum (median 30) number of reuses changed little during 1991­
1997 (Table 7). Sixty-two percent of centers reported using only an automated system for 
reprocessing dialyzers (vs 59% in 1992), 34% only a manual system (vs 33% in 1992), and 5% 
both systems. 
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During 1983-1997, the proportion of centers using formaldehyde for reprocessing 
dialyzers decreased from 94% to 34% (Table 8). The percentage of centers using peracetic acid-
hydrogen peroxide (Renalin™1, Minntech Corporation, Minneapolis, MN) for reprocessing 
dialyzers increased from 5% in 1983 to 56% in 1997, while the use of a glutaraldehyde-based 
germicide (Diacide™, Alden Scientific, Winthrop, MA) increased from less than 1% to 7% 
during the same period. In 1997, 75 (3%) centers used heat to disinfect dialyzers between reuses 
(versus 17 [0.9%] in 1994). 
During December 25-31, 1997 (the time frame for which this information was 
requested), 
59.7% of patients were dialyzed through an arteriovenous graft, 22.8% through an arteriovenous 
fistula, and 17.5% through a temporary or permanent central catheter (Table 9). Since 1995, the 
percent of patients dialyzed through catheters increased from 12.7% to 17.5% (Table 9). Among 
the ESRD networks, use of fistulas (the most desirable access type) ranged from 14.7% to 33.9% 
and central catheters (the least desirable access type) from 11.1% to 24.1% (Table 10). 
Hepatitis B Vaccine and Prevalence of Anti-HBs 
During 1983-1996, the proportion who had ever received at least three doses of hepatitis 
B vaccine increased from 5%-36% among patients and from 26%-82% among staff; in 1997, the 
figures were 46.7% for patients and 86.6% for staff members (Table 11). Note that the survey 
questions on vaccination were changed for the 1997 survey, and referred only to patients treated 
or staff members who worked during the last week of the year (footnote, Table 11). The 
vaccination data may be more accurate for 1997 than for previous years, since determination of 
vaccine status at the end of the year, at the time the survey is completed, should be easier and 
more accurate than determining vaccine status for patients treated (or staff members who 
worked) at any time during the year, as was requested in previous surveys. Among the ESRD 
networks, hepatitis B vaccination among patients in 1997 varied from 29.9% (network 18) to 
58.0% (network 12) (Table 12). The largest absolute increase in vaccination during 1996-1997 
Use of trade names is for identification only and does not constitute endorsement by the Public Health Service 
or the U.S. Department of Health and Human Services. 
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occurred in networks 3 and 14 (Table 12). 
Incidence and Prevalence of HBV Infection 
In 1997, 83% of centers reported screening patients monthly for HBsAg, 1% bimonthly, 
8% quarterly, 3% semiannually, and 3% never. During 1976-1997, the incidence of HBV 
infection decreased from 3.0% to 0.05% among patients and from 2.6% to 0.05% among staff 
members, with the largest decline in both groups occurring during 1976-1980; during the same 
period, the prevalence of HBsAg-positivity among patients and staff members declined from 
7.8% to 0.9% and 0.9% to 0.4%, respectively (Tables 13 and 14). In 1997, 3.3% of centers 
reported $1 patient with newly acquired (incident) HBV infection, 24.1% of centers reported $1 
patient with chronic (prevalent) HBV infection, and 25.5% of centers treated $1 patient with 
either acute or chronic HBV infection. 
In 1997, there was no difference in HBV incidence between centers using a separate 
room and dedicated dialysis machine, with or without separate staff members, to treat HBsAg­
positive patients and centers using only a dedicated machine and no separation practices (Table 
15). As in previous years, reuse of dialyzers was not associated with any increased risk of HBV 
infection in either patients or staff (data not shown). In 1997, 71% of centers accepting HBsAg­
positive patients used both a separate room and dedicated dialysis machine to treat such patients 
(vs 78% in 1989 and 70% in 1993). 
This national surveillance project was initiated primarily because of the high incidence of 
HBV infection reported among hemodialysis patients and staff in the early 1970s (1). 
Hemodialysis patients may acquire HBV infection from community sources, or from 
transmission in hemodialysis centers due to inadequate infection control precautions (13-15) or 
to accidental breaks in technique (16). Factors contributing to the decline in HBV infection 
since the 1970s have been previously reviewed (9). A logistic regression model of data pooled 
from 1992-1994 showed the following independent risk factors for acute HBV infection: 
treatment of an acute or chronic HBV-infected patient the previous year; accepting HBsAg­
positive patients and not treating these patients with a separate room and machine; having <50% 
patients vaccinated against HBV; and receipt of dialysis in California, New Jersey, New York, or 
Texas (10). A case-control study based on the 1995 survey showed that hepatitis B vaccine was 
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approximately 70% effective in preventing newly acquired HBV infection (17). 
HBsAg-positive patients at a dialysis center are a potential source of nosocomial 
transmission. Some centers with a policy of using a separate room and machine for HBsAg­
positive patients may share equipment and staff between infected and susceptible patients, 
risking cross contamination. In 1994, five outbreaks of HBV infection among hemodialysis 
patients were reported from three states (18). In some instances, failure to perform routine 
screening for HBsAg and/or to routinely review screening results led to the failure to recognize 
HBsAg-positive patients and isolate them. In other instances, HBsAg-positive patients were 
isolated in separate rooms with separate machines, but shared staff and equipment with 
susceptible patients. Thus the low incidence of HBV infection among dialysis patients overall 
does not preclude the need to continue to adhere to the specific recommendations for preventing 
transmission of HBV in this setting (Appendices II and III). 
Hepatitis C (Non-A Non-B Hepatitis) 
The incidence of non-A non-B hepatitis in 1997 was reported to be 0.2% among patients 
and 0.07% among staff (Table 16). 
In 1997, 48% of centers tested patients for anti-HCV, and the prevalence of anti-HCV at 
these centers was 9.3% (Table 17). Among the ESRD networks, anti-HCV prevalence ranged 
from 5.5% to 12.4%; networks with higher anti-HCV prevalence rates were more likely to test 
their patients for anti-HCV (Table 18). Anti-HCV prevalence was 9.3% at both centers that 
reused and did not reuse dialyzers. 
In 1997, 25% of centers tested staff for anti-HCV, and the prevalence of anti-HCV at 
these centers was 1.6% (Table 17). Anti-HCV prevalence among staff was similar at centers 
that reused (1.6%) and did not reuse (1.7%) dialyzers (p=0.9). 
Outbreaks of non-A, non-B hepatitis, a disease primarily transmitted by the bloodborne 
route, have been reported among hemodialysis patients (19,20). The results of the 1997 survey 
show that reported incidence rates of non-A non-B hepatitis continue at low levels among 
patients and staff. However, difficulty in diagnosing this syndrome, including the fact that 
approximately 75% of cases of non-A non-B hepatitis in healthy adults are asymptomatic, may 
make these reported rates unreliable. Recommendations for detection and prevention of non-A 
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non-B hepatitis and hepatitis C in hemodialysis units have been published (21,22) (Appendix 
IV). 
In the United States, 80-90% of cases of non-A non-B hepatitis are reportedly caused by 
HCV (23). Interpretation of the results of enzyme immunoassays (EIAs) that screen for anti-
HCV is limited by several factors: 1) these assays will not detect anti-HCV in 10%-20% of 
hemodialysis patients infected with HCV; 2) these assays do not distinguish between acute and 
chronic or past infection; 3) in the acute phase of HCV infection, there may be a prolonged 
interval between onset of illness and seroconversion; and 4) in populations with a low 
prevalence of infection, the rate of false positivity for anti-HCV is high, and the positive 
predictive value of the tests is low. 
Monthly determination of liver enzymes, rather than of anti-HCV, is recommended for 
screening for both non-A non-B hepatitis and hepatitis C (21,22). This recommendation has 
been made because non-A non-B hepatitis can be caused by agents (viral or nonviral) other than 
HCV; and, if caused by HCV, anti-HCV may not be detectable or may be found only after a 
prolonged interval following exposure or onset of hepatitis (24-28). Thus, acute non-A, non-B 
hepatitis remains a diagnosis of exclusion (29), even with the availability of a licensed test for 
anti-HCV. Issues surrounding prevention of HCV transmission in long-term hemodialysis 
settings are currently undergoing discussion, and an update of recommendations is being 
considered. 
Vancomycin Use and Vancomycin-Resistant Enterococci (VRE) 
The median percent of patients receiving vancomycin in December decreased from 5.6% 
in 1995 to 4.5% in 1997. In 1997, vancomycin use was higher at smaller centers, centers owned 
by governments, and at centers treating a higher percentage of patients with central catheters 
(Table 19). Additionally, vancomycin use varied among the ESRD networks from 2.7% of 
patients in network 17 to 6.9% of patients in network 3 (Table 20). 
The percentage of centers reporting $1 patients with VRE increased from 11.5% 
(303/2,634) in 1995 to 29.8% (918/3077) in 1997. In 1997, VRE was reported more often from 
centers that treated patients with MRSA, government centers, and hospital (vs freestanding) 
centers (Table 21). Among the ESRD networks, reporting of VRE varied from 13.3% (network 
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7) to 57.7% (network 1) (Table 22). 
VRE, first reported in 1989 among renal failure patients in England (30), has emerged as 
a major nosocomial pathogen. At 189 hospitals reporting to CDC’s National Nosocomial 
Infections Surveillance (NNIS) system, the percentage of enterococcal isolates from all body 
sites that were resistant to vancomycin increased from 0.3% in 1989 to 10.5% in 1997 (31,32). 
Numerous outbreaks have been reported (33,34). In three studies of hospitalized patients 
infected or colonized with VRE conducted by CDC, patients receiving dialysis comprised 12% 
(3/26) (35) (CDC, unpublished data), 17% (8/46) (34), and 22% (20/93) (36); CDC, unpublished 
data) of such patients. A recent surveillance study at 49 hospitals showed that receipt of 
hemodialysis or peritoneal dialysis was an independent risk factor for VRE bacteremia (37). 
Risk factors for VRE include severity of illness and receipt of antibiotics, particularly 
vancomycin (38). “Recommendations for Preventing the Spread of Vancomycin Resistance,” 
including guidelines for prudent vancomycin use, have been published (38) and additional 
information specific to dialysis units is provided in Appendix II. 
The data reported here on treatment of VRE patients are limited in that the survey does 
not distinguish between clinical infection and colonization (i.e., positive culture for the organism 
without invasive infection). Centers that perform surveillance for VRE with stool or rectal 
cultures, or that treat patients from hospitals where such culturing is done, would be more likely 
to report VRE colonized patients, introducing “surveillance bias.” 
Methicillin-Resistant Staphylococcus Aureus (MRSA) 
The percentage of centers reporting $1 patients with MRSA increased from 40.3% 
(1,056/2,620) in 1995 to 55.9% (1,720/3,077) in 1997. 
S. aureus is the most common cause of vascular access infections and related bacteremias 
in hemodialysis patients (39,40). At hospitals reporting to the NNIS system, the percentage of S. 
aureus isolates resistant to methicillin (i.e., MRSA) increased from 2.4% in 1975 to 29% in 
1991 (41). Knowledge of the MRSA prevalence is important in decisions regarding antibiotic 
choice, which in turn is important in preventing the spread of resistance to vancomycin and other 
antibiotics (Appendix II). 
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Tuberculosis 
One or more patients with active tuberculosis requiring treatment was reported by 6.8% 
(210/3,077) of centers. 
The 1997 survey studied the prevalence, rather than the incidence, of active tuberculosis. 
Several studies at individual dialysis centers have reported high incidence rates of tuberculosis 
(42-44). A recent study reported small numbers of patients with active TB in New Jersey during 
1995-1995, with TB rates higher than in the New Jersey general population (45) (unpublished 
data, Theresa Simon, 1996). 
It is thought that ESRD patients who have tuberculous infection without active disease 
are more likely to progress to active tuberculosis because of ESRD-associated 
immunodeficiency. Therefore, CDC recommends that ESRD patients be screened (i.e., 
tuberculin skin tested using the Mantoux technique) for tuberculosis and given preventive 
therapy if they are found to be infected (46,47). CDC also recommends that medical care 
facilities assess the risk of nosocomial transmission of Mycobacterium tuberculosis and develop 
a tuberculosis control plan appropriate for the level of risk (48). 
Bacteremia and Vascular Access Infections 
Centers having a formal system to track bacteremia and vascular access infections were 
asked to report the number of these events during 1997. To calculate rates per patient-year, we 
used the number of patients dialyzed at each center during December 25-31, 1997 as an estimate 
of the average daily census during 1997; this number would then equal the total patient-years for 
that unit during the year. Among 1,973 centers, the reported bacteremia rate was 10.1 per 100 
patient-years (13,985/138,559). Among 1,983 centers, the reported rate of vascular access 
infection without bacteremia was 9.5 per 100 patient-years (12,949/135,926). 
Bacteremia in hemodialysis patients may be secondary to vascular access infections or to 
infections at other sites (e.g., lung, gastrointestinal tract, or genitourinary tract) (49). Rates of 




Twenty-one percent of centers reported pyrogenic reactions in the absence of septicemia 
among their patients (Table 23). 
Since 1989, when changes were made in the survey instrument, 19-22% of centers have 
reported pyrogenic reactions in the absence of septicemia. Possible mechanisms by which 
certain practices (reuse of dialyzers; use of bicarbonate dialysate, high flux dialyzer membranes, 
or high flux dialysis) may cause pyrogenic reactions have been presented in previous reports (6­
8). 
New Dialyzer Syndrome 
New dialyzer syndrome was reported in patients by 23% of centers in 1997. The 
proportion reporting this complication has decreased from 43% of centers in 1984 (Table 24). 
Human Immunodeficiency Virus Infection 
During 1985-1997, the percentage of centers that reported providing dialysis for patients 
with HIV infection increased from 11% to 39% (Table 25). In 1997, 1.3% (range among the 
networks 0.2%-3.1%) of patients were reported to have HIV infection and 0.6% (range among 
the networks 0%-1.4%) to have AIDS (Tables 25-26). Since a minority of centers routinely test 
for HIV (see below), these figures may be underestimates. 
Since 1989, there have been small decreases in the proportions of centers testing patients 
for anti-HIV on admission (28% in 1989 and 22% in 1997) or routinely after admission (17% in 
1989 and 12% in 1997). 
Transmission of HIV in dialysis centers has been reported in developing countries (53­
55), and an instance of transmission of HIV from a dialysis patient with known HIV infection to 
a staff member via a needlestick injury has been reported in the U.S. (CDC, unpublished data). 
Otherwise, there have been no reports of nosocomial HIV transmission in dialysis centers, and 
the likelihood of such transmission appears to be low when standard barrier or universal 
precautions are practiced. Patients with HIV infection can receive either hemodialysis or 
peritoneal dialysis without additional precautions, such as isolation from other patients by either 
room or machine (56,57). Additionally, routine testing of dialysis patients or staff for anti-HIV 
for purposes of infection control is not necessary. 
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Table 1 
Numbers of Hemodialysis Centers, Patients, and Staff Surveyed, 
United States, 1985-1997
 No. of Patients No. of Staff Median
 No. of Median Median Patient/Staff 
Year Centers Total Per Center Total Per Center Ratio 
1985 1,250 80,151 50 24,034 15 3.4 
1986 1,350 87,505 51 25,044 15 3.5 
1987 1,486 97,225 52 27,123 14 3.6 
1988 1,586 107,804 55 28,501 14 3.7 
1989 1,726 122,734 56 32,486 15 3.8 
1990 1,882 140,608 59 36,907 16 3.8 
1991 2,046 155,877 63 40,298 16 3.8 
1992 2,170 170,028 64 43,535 17 3.9 
1993 2,304 180,341 65 45,943 16 3.9 
1994 2,449 206,884 72 50,353 17 4.1 
1995 2,647 224,954 71 54,194 17 4.2 
1996 2,808 229,527 70 59,882 18 3.9 
1997 3,077 253,001 71 63,054 17 4.1 
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Table 2 
Location and Ownership of Hemodialysis Centers, 
1985-1997, United States
 Percent of Hemodialysis Centers 
Location Ownership 
Free- Non-
Year Hospital standing Profit profit Government 
1985 44 56 46 44 11 
1986 42 58 49 41 10 
1987 39 61 51 40 9 
1988 37 63 53 39 8 
1989 35 65 55 38 7 
1990 34 66 56 37 7 
1991 35 65 56 35 9 
1992 33 67 57 34 9 
1993 31 69 62 32 6
 1994 29 71 62 31 6
 1995 27 73 63 30 7
 1996 26 74 66 28 6
 1997 23 77 70 25 5 
           
                                       
                                        
                                        
                                        
                                        
                                        
                                        
                                       
                                       
                                       
                           
       




Dialyzer Membrane Types Used by Hemodialysis Centers
 
1988-1997, United States 

Percent of Centers Using*

 Conventional Dialyzers High Flux Dialyzers† Any

 Cellulose Regenerated Cellulose Poly- High Flux
 
Year Cuprophan Acetate Cellulose Triacetate PAN sulfone PMMA Dialyzer
 
1988 76 59 16 -- 4 17 1 23
 
1989 78 57 14 3 4 22 1 29
 
1990 75 55 15 3 5 26 1 34
 
1991 70 60 15 4 4 34 1 41
 
1992 63 55 15 5 3 43 3 50
 
1993 59 56 18 7 3 52 4 59
 
1994 50 54 18 9 3 59 4 67
 
1995 44 49 18 13 2 69 4 77 

1996 36 44 17 12 2 78 4 84 

1997 27 43 12 14 2 80 3 87 

* Total >100% for each year since many centers use >1 dialyzer membrane. 

† PAN denotes polyacrylonitrile; PMMA denotes polymethylmethacrylate.
 
        
                     
                     
              
             
             
             
            
           
           
           
          
                                     









No. (%) No. (%)
 High Flux Dialysis High Efficiency Dialysis 
Year Centers Patients Centers Patients
1987 224 (15) 5,057 ( 5) -- -­
1988 284 (18) 8,351 ( 8) -- -­
1989 387 (22) 12,658 (10) 396 (23) 9,598 ( 8) 
1990 478 (25) 17,363 (12) 528 (28) 14,587 (10) 
1991 624 (30) 26,379 (17) 642 (31) 19,456 (12) 
1992 765 (35) 35,862 (21) 823 (38) 26,737 (16) 
1993 899 (39) 48,192 (27) 1027 (45) 39,016 (22) 
1994 1094 (45) 63,266 (31) 1259 (51) 53,439 (26) 
1995 1331 (50) 82,732 (37) 1650 (62) 69,670 (31) 
1996 1620 (58) 95,062 (42) 1860 (67) 80,297 (35) 
1997 1924 (63) 116,730 (46) 2161 (70) 94,402 (37) 
* Dialyzer UFR $20 
† Dialyzer UFR 10-19; information on high efficiency dialysis was not

 collected until 1989.
 
                
                
                 
                 
                 
                
                 
                 
                
                 
                 
                 








 No. (%) of Centers
 
Year None RO* DI† RO and DI Other 
1980 52 ( 5) 187 (19) 137 (14) 72 ( 7) 520 ( 54) 
1984 24 ( 2) 572 (47) 168 (14) 404 (34) 37 ( 3) 
1987 8 ( 1) 754 (51) 143 (10) 558 (38) 23 ( 2) 
1989 1 (<1) 884 (51) 118 ( 7) 689 (40) 33 ( 2) 
1990 0 ( 0) 1015 (54) 122 ( 6) 750 (40) 5 (0.3) 
1991 0 ( 0) 1106 (54) 110 ( 5) 814 (40) 16 ( 1) 
1992 0 ( 0) 1201 (55) 99 ( 5) 852 (39) 18 ( 1) 
1993 0 ( 0) 1268 (55) 84 ( 4) 937 (41) 15 ( 1) 
1994 0 ( 0) 1338 (55) 78 ( 3) 1019 (42) 14 ( 1) 
1995 0 ( 0) 1470 (56) 74 (3) 1076 (41) 27 ( 1) 
1996 0 ( 0) 1617 (58) 51 (2) 1114 (40) 22 ( 1) 





      
             
             
           
           
           
           
           
           
         
         
         
         
         
         
         
         
         
         








 Total No. (%) 

Year Centers Reusing 

1976 750 135 (18) 

1980 956 179 (19) 

1982 1,015 435 (43) 

1983 1,120 579 (52) 

1984 1,201 693 (58) 

1985 1,250 764 (61) 

1986 1,350 855 (63) 

1987 1,486 948 (64) 

1988 1,586 1,058 (67) 

1989 1,726 1,172 (68) 

1990 1,882 1,310 (70) 

1991 2,046 1,453 (71) 

1992 2,170 1,569 (72) 

1993 2,304 1,688 (73) 

1994 2,449 1,835 (75) 

1995 2,647 2,048 (77) 

1996 2,808 2,261 (81) 

1997 3,077 2,523 (82) 

                          
                         
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
 
    




Frequency of Dialyzer Reuse Reported by Hemodialysis
 
Centers, 1986-1997, United States

 No. of Average Reuses Maximum Reuses 

Year Centers Mean Median Range Mean Median Range

 1986 841 10 9 3-70 26 23 3-106

 1987 943 11 10 1-85 27 25 4-119

 1988 1058 11 10 2-50 28 25 3-131

 1989 1172 12 10 1-50 28 25 3-150

 1990 1310 13 12 1-50 30 30 3-131

 1991 1453 14 13 2-50 32 30 3-181

 1992 1659 14 13 1-50 33 30 5-264

 1993 1688 15 13 2-60 33 30 5-149

 1994 1835 15 14 1-55 35 30 1-160

 1995 2048 15 14 1-80 36 30 1-192 

1996 2261 15 14 1-56 37 30 1-155 

1997 3077 17 15 1-65 38 30 1-179 

    
                                     
                                     
                                     
                                     
                                      
                                     
                                      
                                      
                                      
                                     
                                      
                                      
                                     
                                     
                                     
         




Chemical Germicides for Reprocessing Dialyzers
 
in Hemodialysis Centers, 1983-1997, United States

 Percentage of Centers 

Peracetic Glutaral­
Formaldehyde* Acid dehyde Heat 
Year All <4.0% $4.0%† Unknown‡ 
1983 94 57 28 15 5 <1 -­
1984 86 43 42 14 12 3 -­
1985 80 43 47 10 17 3 -­
1986 69 40 48 12 28 3 -­
1987 62 42 51 7 34 4 -­
1988 54 50 40 10 40 6 -­
1989 47 58 37 5 46 7 -­
1990 43 62 33 5 49 8 -­
1991 42 66 32 2 50 9 -­
1992 40 68 32 0 52 8 <1 
1993 40 67 33 0 51 8 1 
1994 40 70 30 0 52 7 1 
1995 38 -- -- -- 54 7 1 
1996 36 -- -- -- 54 7 3 
1997 34 -- -- -- 56 7 3 
* 	 The percentage of centers listed for each concentration of formaldehyde

 is the percentage of total formaldehyde users (data not collected in 1995­
1997).
 
† 	 Concentration recommended by CDC if dialyzer is stored at room temperature.
 
‡ 	 Unknown concentration of formaldehyde
 





Type of Vascular Access Used for Hemodialysis, 1995-1997, United States
 
Number of Percent of Patients Dialyzed Through*
 
Year Patients Fistula Graft Catheter 
1995 153,320  22.2  65.1  12.7 
1996 176,609  22.1  62.9  14.9 
1997 195,588  22.8  59.7  17.5 




      
                                   
                             
                                 
                          
                             
                              
                             
                           
                                 
                                   
                      
                                    
                       
                     
                        
                                 
                                   
                     
                             
                       




Vascular Access by End Stage Renal Disease (ESRD) Network, 

December 25-31, 1997, United States

 ESRD States, Districts, Total Percent Dialyzed Through 
Network or Territories Patients Fistula Graft Catheter
 14 TX 15,850 14.7 70.3 14.9
 8 AL MS TN 11,698 16.9 70.5 12.6
 18 S.CA 14,129 18.2 70.6 11.1
 5 DC MD VA WV 13,040 18.9 64.4 16.7
 6 GA NC SC 18,207 19.3 63.7 17.0
 13 AR LA OK 8,767 19.6 63.1 17.3
 9 IN KY OH 12,945 22.1 53.8 24.1
 12 IA KS MO NE 6,477 22.2 57.6 20.2
 4 DE PA 9,690 23.5 54.4 22.2
 7 FL 11,552 23.7 55.2 21.1
 17 AS GU HI MP N.CA 9,587 23.8 65.0 11.1
 10 IL 8,822 24.2 53.5 22.3
 11 MI MN ND SD WI 12,020 24.3 57.4 18.2
 15 AZ CO NM NV UT WY 7,086 26.5 55.0 18.4
 16 AK ID MT OR WA 4,632 27.3 57.9 14.8
 3 NJ PR 8,895 32.1 45.0 22.9
 2 NY 14,694 32.8 51.9 15.4 
1 CT MA ME NH RI VT 7,497 33.9 46.6 19.4
 All 195,588 22.8 59.7 17.5
 Rows are sorted by percent dialyzed through a fistula.
 
            
            
            
            
          
          
          
          
          
          
          
          
          
          
         








 No. (%) Ever Receiving

 Three Vaccine Doses 

Year Patients Staff
 1983 3,619 ( 5.4) 5,670 (26.1)
 1984 4,495 ( 6.0) 7,181 (31.6)
 1985 6,290 ( 7.8) 8,521 (35.5)
 1986 8,815 (10.1) 9,877 (39.4)
 1987 12,270 (12.8) 11,316 (41.9)
 1988 17,019 (15.8) 12,949 (45.5)
 1989 21,623 (17.6) 15,578 (48.0)
 1990 24,260 (18.2) 19,311 (53.0)
 1991 25,397 (16.9) 22,499 (56.1)
 1992 37,459 (23.6) 30,069 (69.4)
 1993 47,183 (28.8) 34,885 (76.1)
 1994 61,492 (31.0) 40,008 (79.6)
 1995 74,217 (35.0) 44,542 (82.4)
 1996 79,133 (36.0) 48,817 (81.9)
 1997 87,749 (46.7)* 43,341 (86.6)* 
* For 1997, the figures are based on patients who were being treated during
 
December 25-31, or staff members who were working during December 25-31. For
 
previous years, the figures are based on patients treated at any time during
 
the year, or staff members who worked at any time during the year.
 
    
                                  
                                     
                                     
                                 
                      
                     
                            
                      
                               
                              
                                    
                                 
                               
                          
                              
                                    
                             
                         
                               
                            




Use of Hepatitis B Vaccine in Hemodialysis Patients
 
by End Stage Renal Disease (ESRD) Network, 1995-1997, United States
 
ESRD State(s), Districts, Percent Vaccinated  Absolute Percent 
Network or Territories 1996 1997 Change Change
 18 S.CA 18.3 29.9 11.6 63.4
 10 IL 22.3 31.5 9.2 41.3
 2 NY 27.8 36.5 8.7 31.3
 3 NJ PR 19.6 37.4 17.8 90.8
 17 AS GU HI MP N.CA 24.9 39.0 14.1 56.6
 15 AZ CO NM NV UT WY 31.5 42.8 11.3 35.9
 5 DC MD VA WV 39.3 45.5 6.2 15.8
 1 CT MA ME NH RI VT 40.7 47.2 6.5 16.0
 9 IN KY OH 38.7 47.7 9.0 23.3
 13 AR LA OK 38.6 50.9 12.3 31.9
 7 FL 40.5 52.0 11.5 28.4
 4 DE PA 40.7 53.0 12.3 30.2
 8 AL MS TN 45.7 53.7 8.0 17.5
 11 MI MN ND SD WI 49.8 54.1 4.3 8.6
 6 GA NC SC 40.4 54.5 14.1 34.9
 14 TX 37.2 55.0 17.8 47.8
 12 IA KS MO NE 51.8 55.2 3.4 6.6 
16 AK ID MT OR WA 48.4 58.0 9.6 19.8
 All 36.0 46.7 10.7 29.7 
Rows are sorted by percent vaccinated in 1997. 
                              
                              
                              
                              
                              
                              
                              
                              
                             
                             
                            
                            
                            
                            
                            
                      
                      
                      








Year Total* Incidence* Total† Prevalence†

 1976 33,875 3.0 22,876 7.8

 1980 62,723 1.0 43,796 3.8

 1982 66,326 0.5 49,275 2.7

 1983 67,229 0.5 54,343 2.4

 1984 76,327 0.3 60,782 2.3

 1985 80,151 0.3 62,172 2.1

 1986 87,505 0.3 67,387 1.9

 1987 97,225 0.2 74,249 1.7

 1988 107,804 0.2 80,651 1.5

 1989 122,734 0.1 90,596 1.4

 1990 140,608 0.2 101,763 1.2

 1991 155,877 0.2 116,651 1.3

 1992 170,028 0.1 128,264 1.2

 1993 180,341 0.1 135,798 1.2

 1994 206,884 0.1 149,743 1.1

 1995  224,954 0.06 162,970 1.1

 1996  229,527 0.08 177,324 1.1

 1997  253,001 0.05 195,935 0.9
 
* Total denotes patients treated at any time during the year, and
 
incidence the percent of such patients who converted to HBsAg-positive.
 
† Total denotes patients treated during one week of December, and
 
prevalence the percent of such patients who were HBsAg-positive.
 
                         
                             
                             
                             
                             
                             
                             
                             
                             
                             
                            
                            
                            
                            
                            
                            
                            
                            








Year Total* Incidence* Total† Prevalence†

 1976 15,946 2.6 ND‡

 1980 20,057 0.8 15,603 0.9

 1982 20,356 0.6 16,235 0.5

 1983 21,688 0.5 18,714 0.6

 1984 22,912 0.3 19,793 0.5

 1985 24,034 0.2 20,346 0.3

 1986 25,044 0.1 21,094 0.4

 1987 27,123 0.1 22,334 0.4

 1988 28,501 0.1 23,778 0.3

 1989 32,486 0.1 26,112 0.3

 1990 36,907 0.04 29,252 0.3

 1991 40,298 0.04 33,079 0.3

 1992 43,535 0.03 36,000 0.3

 1993 45,943 0.02 37,992 0.3

 1994 50,353 0.02 40,951 0.3

 1995 54,194 0.02 43,465 0.4

 1996 59,882 0.05 47,215 0.3

 1997 63,054 0.05 50,321 0.4
 
* Total denotes staff who worked at any time during the year, and
 
incidence the percent of such staff who converted to HBsAg-positive.
 
† Total denotes staff who worked during one week of December, and
 





                      
                     
                     
                     
                     
                      
                      
                     
                     
                    
                    
                    
                  
                       
                      
     
     
     
    




Effect of Separation Practices for HBsAg-Positive Patients on
 




 Incidence of HBsAg (%) 





Year Machine Only None
 
1976 3.9* -- 6.8
 
1980 0.8* 2.0 1.5
 
1983 0.5* 0.9 1.1
 
1987 0.3* 0.5 1.7
 
1989 0.2† 0.2 0.6
 
1990 0.3 0.3 0.5
 
1991 0.3 0.3 0.5
 
1992 0.2* 0.4 0.3
 
1993 0.2* 0.4 0.4†
 
1994 0.18 0.21 0.13
 
1995 0.09 0.14 0.05 

1996 0.13 0.16 0.05 

1997 0.055 0.038 0.037 

Note: Only centers with $1 HBsAg-positive patient are included. 
* P<0.05, room and machine vs machine only and none
 
† P<0.05, room and machine vs none
 
      
               
                 
                 
                 
                 
                 
                
                
                
                
                
                
                
                
                
                




Incidence of Non-A Non-B Hepatitis in Hemodialysis
 
Patients and Staff, 1982-1997, United States

 Total Incidence Total Incidence
 
Year Patients* (%) Staff* (%) 

1982 60,326 1.7 ND†

 1983 61,778 1.8 19,276 0.5 

1984 74,923 1.6 22,865 0.3 

1985 80,151 1.4 24,034 0.2 

1986 87,760 1.5 25,044 0.2 

1987 96,554 1.2 27,123 0.2 

1988 106,826 1.0 28,501 0.1 

1989 122,734 0.7 32,486 0.1 

1990 140,608 0.5 36,907 0.1 

1991 155,435 0.5 40,298 0.1 

1992 169,340 0.5 43,535 0.1 

1993 180,139 0.6 45,904 0.1 

1994 206,273 0.4 50,353 0.1 

1995 224,358 0.3 50,028 0.05 

1996 227,197 0.4 59,480 0.04 

1997 249,194 0.2 62,482 0.07 

* Patients and staff at centers not supplying information on non-A





                    
          
                    
                  
                  
                  
                  
                  
                           
                      
                     
                     
                     
                    




Antibody to Hepatitis C Virus (anti-HCV) Testing and Prevalence 

among Hemodialysis Patients and Staff, 1992-1997, United States

 Percent Anti-HCV
 of Centers Total Prevalence 
Group Year Testing Tested No. (%) 
Patients 1992 22 27,086 2,202 (8.1)
 1993 29 37,654 3,654 (9.7)
 1994 34 50,438 5,306 (10.5)
 1995 39 61,400 6,362 (10.4) 
1996 44 75,601 7,652 (10.1) 
1997 48 91,098 8,434 (9.3) 
Staff 1992 10 2,889 45 (1.6)
 1993 15 4,825 75 (1.6)
 1994 16 5,679 106 (1.9)
 1995 16 6,238 122 (2.0)
 1996 20 8,472 113 (1.3)
 1997 25 11,649 190 (1.6) 
                  
                                  
                         
                            
                                     
                                  
                                     
                                      
                                      
                                
                                
                        
                                
                       
                                    
                             
                                
                           
                       
                               
                                    





Antibody to Hepatitis C Virus (anti-HCV) Testing and Prevalence Among
 




 Centers Patients 

ESRD States, Districts, Test for Total Anti-HCV
 
Network or Territories Total Anti-HCV (%) Tested Positive (%)

 3 NJ PR 101 54.5 4,771 12.4

 11 MI MN ND SD WI 227 38.3 5,502 12.2

 5 DC MD VA WV 214 50.5 6,569 12.1

 2 NY 159 59.1 8,284 12.0

 4 DE PA 158 62.7 5,831 10.0

 14 TX 228 45.6 6,666 10.0

 7 FL 210 49.0 5,725 9.6

 10 IL 106 34.9 2,670 9.1

 13 AR LA OK 183 71.6 6,478 9.1

 8 AL MS TN 210 52.9 5,439 8.7

 17 AS GU HI MP N.CA 125 40.0 3,261 8.5

 6 GA NC SC 298 51.7 9,560 7.3

 1 CT MA ME NH RI VT 111 51.4 3,804 7.2

 18 S.CA 173 36.4 4,685 6.8

 12 IA KS MO NE 153 43.8 2,661 6.5

 9 IN KY OH 199 34.2 4,165 6.1

 16 AK ID MT OR WA 89 37.1 1,603 5.7
 
15 AZ CO NM NV UT WY 133 46.6 3,424 5.5

 All 3077 48.2 91,098 9.3
 
Rows are sorted by percent anti-HCV positive
 
    
                           
                        
                
                  
                    
        
                     
            
            
                      
               
             
             
             
             
                 




Receipt of Vancomycin by Chronic Hemodialysis Patients, 

by Center Characteristic, United States, December 1997

 Total Received 

Factor Patients Vancomycin* P-Value†

 All 184,638 4.5 -­
Size

 1-40 25,045 5.3 0.009

 41-80 62,459 4.8





 Hospital 36,953 4.6 0.6





 Profit 130,967 4.5 0.02

 Nonprofit 49,632 4.5





0-4.9% 14,970 3.0 0.0001

 5-9.9% 33,181 3.5

 10-14.9% 38,963 4.3

 15-19.9% 30,611 4.7

 20-24.9% 24,935 5.4

 25-29.9% 16,059 4.7

 30%+ 27,667 6.0
 
* 	 Median percent of patients receiving vancomycin in December 1997
 
† 	 Wilcoxon test for heterogeneity among the groups
 




    
                       
                                     
                          
                                   
                      
                               
                                      
                      
                                  
                               
                         
                            
                            
                               
                               
                                     
                                     
                                   
                                
                               




Receipt of Vancomycin by Chronic Hemodialysis Patients, 

by End Stage Renal Disease (ESRD) Network, United States, 





 ESRD States, Districts, Centers Received Vancomycin* Absolute
 
Network or Territories 1997 1996 1997 Change

 17 AS GU HI MP N.CA 125 3.1 2.7 -0.4

 14 TX 218 4.5 3.4 -1.1

 16 AK ID MT OR WA 84 4.2 3.4 -0.8

 18 S.CA 162 3.8 3.5 -0.3

 15 AZ CO NM NV UT WY 127 4.7 3.9 -0.8

 8 AL MS TN 191 5.1 4.0 -1.1

 10 IL 97 4.8 4.4 -0.4

 1 CT MA ME NH RI VT 107 5.8 4.5 -1.3

 4 DE PA 150 4.8 4.5 -0.3

 6 GA NC SC 283 5.1 4.5 -0.6

 11 MI MN ND SD WI 211 5.6 4.5 -1.1

 5 DC MD VA WV 213 5.3 4.7 -0.6

 12 IA KS MO NE 146 5.7 5.0 -0.7

 13 AR LA OK 180 6.8 5.4 -1.4

 9 IN KY OH 190 6.3 5.5 -0.8

 2 NY 144 6.3 5.6 -0.7

 7 FL 204 6.2 6.1 -0.1

 3 NJ PR 96 7.7 6.9 -0.8

 All 2928 5.2 4.5 -0.7
 
* Median percent of patients receiving vancomycin in December of 1996
 
or 1997 (rows are sorted on this value for 1997)
 
         
                             
                          
                        
                       
                    
                    
                     
                 




Reporting of One or More Patients with Vancomycin-Resistant 

Enterococci (VRE), by Center Characteristic, United States, 1997

 Total No (%) Relative
 
Factor Centers with VRE Risk P-value*

 All 3077 918 (29.8) -- -­
Treat MRSA Patients

 No 1356 191 (14.1) 1.0 Ref





 Profit 2152 569 (26.4) 1.0 Ref

 Nonprofit 770 280 (36.4) 1.4 <0.001





 Hospital 722 288 (39.9) 1.5 <0.001

 Freestanding 2354 630 (26.8) 1.0 Ref

 Ref denotes reference category

 * Compared with reference category
 
      
  
                                 
                           
                           
                                 
                     
                           
                  
                        
                     
                           
                              
                       
                               
                  
                                
                                
                             
                 
                           
                             
                       




Reporting of One or More Patients with Vancomycin-Resistant Enterococci (VRE),
 
by End Stage Renal Disease (ESRD) Network, United States, 1995-1997

 Percent of Absolute

 ESRD States, Districts Centers Reporting VRE  Change
 
Network or Territories 1995 1997 1995-1997

 7 FL 2.8 13.3 10.5

 8 AL MS TN 2.9 14.8 11.9

 13 AR LA OK 1.9 14.8 12.9

 14 TX 9.8 20.2 10.4

 16 AK ID MT OR WA 9.5 20.2 10.7

 6 GA NC SC 7.4 20.8 13.4

 15 AZ CO NM NV UT WY 5.8 28.6 22.8

 5 DC MD VA WV 8.7 29.0 20.3

 11 MI MN ND SD WI 7.4 31.7 24.3

 9 IN KY OH 6.7 33.2 26.5

 3 NJ PR 28.2 35.6 7.4

 12 IA KS MO NE 12.1 35.9 23.8

 18 S.CA 7.9 38.2 30.3

 17 AS GU HI MP N.CA 18.4 38.4 20.0

 2 NY 29.5 39.6 10.1

 10 IL 16.7 44.3 27.6

 4 DE PA 27.7 56.3 28.6

 1 CT MA ME NH RI VT 30.7 57.7 27.0

 All 11.5 29.8 18.3

 Rows are sorted by percent reporting VRE in 1997
 
                          
                          
                       
                       
                       
                       
                      
                       
                       
                      
                       
                       
                       
                       
                       
                       
                       
                       




Frequency of Pyrogenic Reactions (PR) Reported by
 
Hemodialysis Centers, 1976-1997, United States

 No. (%) Centers Reporting
 
Year Total Centers $1 PR PR Clusters

 1976 540 72 (13) --*

 1980 956 97 (10) -­
1982 1,017 109 (11) -­
1983 1,135 131 (12) -­
1984 1,203 134 (11) -­
1985 1,251 131 (11) -­
1986† 1,350 213 (16) 33 (2.4)

 1987 1,485 205 (14) 38 (2.6)

 1988 1,586 231 (15) 54 (3.4)

 1989‡ 1,726 383 (22) 47 (2.7)

 1990 1,882 377 (20) 61 (3.2)

 1991 2,046 402 (20) 62 (3.0)

 1992 2,170 419 (19) 67 (3.1)

 1993 2,304 481 (21) 68 (3.0)

 1994 2,449 528 (22) 59 (2.4)

 1995 2,647 511 (20) 45 (1.7) 

1996 2,808 577 (21) 49 (1.7) 

1997 3,077 648 (21) 53 (1.7) 

* Information not collected until 1986

 † 1976-1985, reporting for a 3-month period only; 	 1986-1997,

 reporting for entire year.





           
                            
                            
                            
                            
                            
                            
                            
                            
                            
                            
                            
                            
                            
                            
                                   




Frequency of New Dialyzer Syndrome 

Reported by Hemodialysis Centers, United States, 1984-1997

 Total Number (%) Centers 
Year Centers Reporting Reactions
 1984 1201 498 (43)
 1985 1250 467 (38)
 1986 1350 544 (40)
 1987 1486 576 (39)
 1988 1586 633 (40)
 1989 1726 539 (31)
 1990 1882 530 (28)
 1991 2046 578 (28)
 1992 2170 527 (24)
 1993 2304 620 (27)
 1994 2449 674 (28)
 1995 2647 622 (24)
 1996 2808 597 (21)
 1997 3077 693 (23) 
           
   
                     
                 
                 
               
               
               
               
             
             
             
            
            
            




Chronic Hemodialysis Centers Reporting Patients
 
with HIV Infection, 1985-1997, United States

 No.(%)of No.(%) of No.(%) of
 Centers with Patients with Patients with 
Year  HIV Infection HIV Infection Clinical AIDS
 1985 134 (11) 244 (0.3) -
1986 238 (18) 546 (0.6) 332 (0.4)
 1987 351 (24) 924 (1.0) 462 (0.5)
 1988 401 (25) 1,253 (1.2) 670 (0.6)
 1989 456 (26) 1,248 (1.0) 663 (0.5)
 1990 493 (26) 1,533 (1.1) 739 (0.5)
 1991 601 (29) 1,914 (1.2) 967 (0.6)
 1992 737 (34) 2,501 (1.5) 1,126 (0.7)
 1993 792 (34) 2,780 (1.5) 1,350 (0.7)
 1994 914 (37) 3,144 (1.5) 1,593 (0.8)
 1995 1022 (39) 3,090 (1.4) 1,606 (0.7)
 1996 1088 (39) 3,112 (1.4) 1,512 (0.7)
 1997 1214 (39) 3,298 (1.3) 1,501 (0.6) 
     
                                 
                                    
                           
                                    
                              
                                    
                      
                                 
                                    
                              
                              
                        
                      
                                  
                              
                            
                      
                         
                              
                                           
 
                  
         




Chronic Hemodialysis Centers Reporting Patients with HIV Infection/AIDS, 

by End Stage Renal Disease (ESRD) Network, 1997, United States

 ESRD States, Districts Total Percent with 

Network or Territories Patients HIV Infection AIDS

 3 NJ PR 11,708 2.6 1.4

 2 NY 18,468 3.1 1.3

 5 DC MD VA WV 16,631 2.7 1.1

 7 FL 15,165 2.1 0.9

 6 GA NC SC 22,679 1.6 0.8

 14 TX 19,681 0.8 0.7

 1 CT MA ME NH RI VT 9,771 1.1 0.5

 4 DE PA 12,859 1.5 0.5

 10 IL 11,374 1.3 0.5

 13 AR LA OK 11,023 0.9 0.5

 8 AL MS TN 14,701 0.8 0.4

 11 MI MN ND SD WI 15,752 0.6 0.3

 17 AS GU HI MP N.CA 11,959 0.8 0.3

 18 S.CA 18,117 0.6 0.3

 9 IN KY OH 16,856 0.5 0.2

 12 IA KS MO NE 8,580 0.5 0.2

 15 AZ CO NM NV UT WY 9,027 0.2 0.1
 
16 AK ID MT OR WA 6,087 0.2 0.0

 All 250,438 1.3 0.6
 
Rows are sorted by percent with AIDS
 
 




Infection Control Precautions for Dialysis Units
 
Dialysis Unit Precautions 
In 1977, CDC published precautions to prevent transmission of HBV in dialysis centers 
(B1). In 1987, universal precautions were developed to prevent transmission of all bloodborne 
pathogens, including HBV and HIV, in health care and other settings (B2). In 1996, an updated 
system of precautions, termed standard precautions, was published to replace universal 
precautions for the hospital and most healthcare settings (B3). The infection control measures 
currently recommended for dialysis units incorporate features of each of these guidelines. These 
measures are effective against HBV, the most highly transmissible organism in hemodialysis units; 
therefore, they should also be effective against other viruses (e.g., HCV) and bacteria (e.g.,VRE). 
Note that dialysis unit precautions are more stringent than universal or standard 
precautions. For example, standard precautions require the use of gloves only when touching 
blood, body fluids, secretions, excretions, or contaminated items. In contrast, dialysis unit 
precautions require glove use whenever patients or hemodialysis equipment is touched. Standard 
precautions do not restrict the use of supplies, instruments, and medications to a single patient; 
dialysis unit precautions specify that none of these be shared between any patients. 
Since dialysis patients may, known or unknown to the staff, be infected or colonized with 
a variety of bacteria and viruses, the following precautions should be used during care of all 
dialysis patients at all times. 
Assign each patient a: (1) dialysis chair or bed and machine; and (2) supply tray 
(tourniquet, antiseptics, if possible blood pressure cuff). Avoid sharing these items. 
Do not share clamps, scissors, other nondisposable items unless sterilized or disinfected 
between patients. 
Prepare and distribute medications from a centralized area. Medication carts should not 
be used. Separate clean and contaminated areas; for example, handling and storage of 
medications and hand washing should not be done in the same or adjacent area to that 
where blood samples or used equipment are handled. 
Disposable gloves should be worn by staff members for their own protection when 
handling patients or dialysis equipment and accessories. Gloves should be worn when 
taking blood pressure, injecting saline or heparin, or touching dialysis machine knobs to 
adjust flow rates. For the patient's protection, the staff member should use a fresh pair of 
gloves with each patient to prevent cross-contamination. Gloves also should be used when 
handling blood specimens. Staff members should wash their hands after each patient 
contact. 
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Avoid touching surfaces with gloved hands that will subsequently be touched with 
ungloved hands before being disinfected. 
Staff members may wish to wear protective eyeglasses and masks for procedures in which 
spurting or spattering of blood may occur, such as cleaning of dialyzers and centrifugation 
of blood. 
Staff members should wear gowns, scrub suits, or the equivalent while working in the unit 
and should change out of this clothing at the end of each day. 
After each dialysis, (1) change linen; (2) clean and disinfect the dialysis bed/chair and 
nondisposable equipment (especially control knobs and other surfaces touched by gloved 
hands). 
Crowding patients or overtaxing staff may facilitate cross- transmission. Avoid clutter and 
allocate adequate space to facilitate cleaning and housekeeping. 
Staff members should not smoke, eat, or drink in the dialysis treatment area or in the 
laboratory. There should be a separate lounge for this purpose. However, all patients may 
be served meals. The glasses, dishes, and other utensils may be cleaned in the usual 
manner by the hospital staff. No special care of these items is needed. 
Hepatitis B Virus (HBV) 
Because HBV is so highly transmissible in hemodialysis centers, several precautions in 
addition to those outlined above have been recommended specifically to deal with this pathogen. 
Patients and staff should be vaccinated and screened as per Appendix III. 
HBsAg-positive patients should undergo dialysis in a separate room designated only for 
HBsAg-positive patients. They should use separate machines, equipment, and supplies, and most 
importantly, staff members should not care for both HBsAg-positive and susceptible patients on 
the same shift or at the same time. If a separate room is not possible, they should be separated 
from HBV susceptible patients in an area removed from the mainstream of activity and should 
undergo dialysis on dedicated machines. Anti-HBs-positive patients may undergo dialysis in the 
same area as HBsAg-positive patients, or they may serve as a geographic buffer between HBsAg­
positive and HBV susceptible patients; in either instance they may be cared for by the same staff 
member. When the use of separate machines is not possible, the machines can be disinfected by 
using conventional protocols, and the external surfaces can be cleaned or disinfected with soap 
and water or a detergent germicide. 
Although there is no evidence that patients or staff members in centers that reuse dialyzers 
are at greater risk of acquiring HBV infection, it might be prudent that HBsAg-positive patients 
not participate in dialyzer reuse programs. HBV can occur in high concentration in blood, and 
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handling dialyzers used on HBsAg-positive patients during the reprocessing procedures might 
place staff members at risk for HBV infection. 
MRSA and VRE 
CDC recommends contact precautions for care of hospitalized patients infected or 
colonized with MRSA, VRE, or certain other antimicrobial-resistant bacteria (B3, B4). Dialysis 
unit precautions as outlined above include many of the measures recommended under contact 
precautions. However, under contact precautions (but not dialysis unit precautions) a private 
isolation room and (in certain instances) a separate gown are recommended. These measures 
were recommended to prevent possible transmission via contaminated environmental surfaces 
such as counter tops and bed rails. Hospitalized patients spend nearly 24 hours a day in their 
hospital bed, whereas dialysis patients spend only 3-5 hours three times a week in the dialysis unit. 
Note that feces are the main reservoir for VRE. The potential for bacterial contamination of 
environmental surfaces would appear to be much greater in hospitalized patients than in most 
dialysis outpatients. 
Dialysis unit precautions should be used for care of all patients; at present we do not 
advise additional precautions for most patients with MRSA or VRE. However, additional 
precautions would be prudent for patients with infective material that can not be contained (e.g., 
wound drainage that can not be contained by dressings and is culture-positive for MRSA or VRE; 
or a positive stool culture for VRE and fecal incontinence, a colostomy, diarrhea, or poor 
hygiene). For these patients, if an isolation room is not available, enhanced attention to patient 
separation and environmental cleaning might be sufficient. Staff should wear a separate gown 
when caring for such patients. 
Dialysis units should reevaluate their compliance with dialysis center precautions and 
improve precautions for care of all patients where necessary. Another approach would be 
cohorting--assign patients with known MRSA or VRE to certain dialysis stations at one end of 
the unit, use dedicated staff to care for them, and ensure that strict precautions are used at these 
stations. 
Prudent Vancomycin Use 
Prudent vancomycin use is another important issue discussed in the CDC guideline 
"Recommendations for Preventing the Spread of Vancomycin Resistance” (B4). Antibiotic use 
can be considered in three categories: prophylaxis given to uninfected patients in an attempt to 
prevent infection; empiric therapy, given to patients with signs and symptoms of infection, 
pending culture results; and continuing therapy, given after culture results are known. 
Prophylaxis with vancomycin should not be given, other than for certain surgical 
procedures (B4). 
Empiric treatment with vancomycin is appropriate, pending culture results, in patients with 
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beta-lactam allergy, or in instances where serious infection with beta-lactam resistant gram-
positive bacteria (i.e., MRSA or Staphylococcus epidermidis, which are generally beta-lactam 
resistant) is likely. Knowing the percent of S. aureus that are methicillin-resistant in your area, 
and the percent of serious infections due to S. epidermidis, is important in determining empiric 
antibiotic coverage. 
Continuing treatment depends on culture results. If the patient has allergy to beta-lactam 
antibiotics, or if beta-lactam resistant bacteria are isolated (with the exception of single blood 
cultures positive for S. epidermidis), vancomycin is appropriate. Depending on susceptibility 
results, alternative antibiotics (e.g., cephalosporins) with dosing intervals $48 hours, which would 
allow post-dialytic dosing, could be used. Recent studies suggest that cefazolin given 3 times a 
week provides adequate blood levels (B5-B6). 
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Recommendations for Hepatitis B Vaccination and Serologic Surveillance 

in Chronic Hemodialysis Patients and Staff
 
The Centers for Disease Control and Prevention (CDC) and the Immunization Practices 
Advisory Committee (ACIP) have published guidelines for protection against infection with 
hepatitis B virus (A1). This appendix is meant to collate, summarize, and update, but not replace, 
sections of these guidelines that deal specifically with hemodialysis patients and staff. If a patient 
or staff member is exposed to hepatitis B virus, the recommendations of the ACIP (A2) should be 
followed. 
Initial Testing for Hepatitis B Virus Markers 
Hemodialysis patients and staff should be tested for hepatitis B surface antigen (HBsAg) 
and antibody to HBsAg (anti-HBs) when they begin dialysis or employment in the center. They 
are classified as infected if HBsAg-positive; immune if anti-HBs positive ($10 milli-international 
units per milliliter [mIU/ml]) on at least two consecutive occasions; or susceptible if HBsAg­
negative and anti-HBs negative (<10 mIU/ml). 
For infection control purposes, testing for antibody to hepatitis B core antigen (anti-HBc) 
is not necessary. However, if testing is done, individuals who are HBsAg-negative and anti-HBc 
positive have had past hepatitis B virus infection and are immune. 
Hepatitis B Vaccination 
All susceptible patients and staff should receive hepatitis B vaccine (dosage schedules in 
Table A1), be tested for anti-HBs 1-2 months after the final dose of vaccine, and be followed up 
as outlined below. Vaccination of immune (anti-HBs $10 mIU/ml on two consecutive occasions) 
persons is not necessary, but also is not harmful. 
Screening and Follow up 
Screening and Follow up depends on the result of anti-HBs testing 1-2 months after the 
final dose of vaccine (Table A2). Unvaccinated immune individuals can be screened and followed 
up as if they were vaccine responders. 
Patients, Responders. Patients who are anti-HBs positive ($10 mIU/ml) after vaccination 
are responders. They should be tested for anti-HBs each year (Table A2). If the level of 
anti-HBs falls below 10 mIU/ml, they should receive a booster dose of hepatitis B vaccine and 
continue to be tested for anti-HBs each year. 
Patients, Non-Responders. Patients who are anti-HBs negative (<10 mIU/ml) after 
vaccination are non-responders. They may be revaccinated with one or more doses of vaccine 
and retested for anti-HBs 1-2 months later. If they are then anti-HBs positive ($10 mIU/ml), they 
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can be reclassified and treated as responders (see above). If they continue to be non-responders 
(anti-HBs <10 mIU/ml), they should be considered susceptible to HBV infection and tested for 
HBsAg every month and anti-HBs every 6 months (Table A2). 
Staff, Responders. Staff who are anti-HBs positive ($10 mIU/ml) after vaccination are 
responders. They do not need any further routine anti-HBs testing (Table A2). If exposed to 
blood from a patient known to be HBsAg-positive, such staff members should be tested for anti-
HBs: if still anti-HBs positive ($10 mIU/ml), no further action is required; however, if they have 
become anti-HBs negative (<10 mIU/ml), they should receive a booster dose of vaccine. 
Staff, Non-responders. Staff who are anti-HBs negative (<10 mIU/ml) after vaccination 
are non-responders. At the center's discretion, they can be revaccinated with one or more doses 
of vaccine, and retested for anti-HBs 1-2 months later. If they then become anti-HBs positive 
($10 mIU/ml), they should be reclassified and treated as responders (see above). If they are not 
revaccinated, or are still anti-HBs negative (<10 mIU/ml) after vaccination, they continue to be 
non-responders. Non-responders should be considered susceptible to HBV infection and tested 
for HBsAg and anti-HBs every 6 months (Table A2). If they are exposed to the blood of a person 
known to be HBsAg-positive, they should either receive 2 doses of hepatitis B immune globulin 
(HBIG), or receive 1 dose of HBIG and 1 dose of hepatitis B vaccine. They may receive similar 
treatment if exposed to the blood of a person known to be at high risk for hepatitis B. 
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Hepatitis B Vaccine Dosage Schedules 
Product/Group Dose Schedule 
Recombivax HB
 Patients 40 µg (1 ml) * 3 doses at 0, 1 and 6 months
 Staff 10 µg (1 ml) 3 doses at 0, 1 and 6 months 
Engerix-B
 Patients 40 µg (2 ml) † 4 doses at 0, 1 ,2 and 6 months
 Staff  20 µg (1 ml) 3 doses at 0, 1 and 6 months or 
4 doses at 0, 1, 2 and 12 months 
* Special formulation
 † Two 1.0-ml doses administered at one site 
Table A2
 




Vaccination/Serologic Status and Frequency of Screening 
Group/ 
Screening Test 
Vaccine Nonresponder or 
Susceptible* 
Vaccine Responder or 
Natural Immunity† 
Chronic HBV Infection‡ 
Patients 
HBsAg Every month None Every year 
Anti-HBs Every 6 months Every year If HBsAg becomes negative 
Staff 
HBsAg Every 6 months None Every year 
Anti-HBs Every 6 months None If HBsAg becomes negative 
* Anti-HBs <10 mIU/ml 
† Anti-HBs >10 mIU/ml 




Recommendations for Screening for Non-A Non-B Hepatitis (Hepatitis C)
 
The assay for antibody to hepatitis C virus (anti-HCV) identifies a high proportion (80% 
to 90%) of persons with chronic hepatitis C. For patients with acute hepatitis C, however, there 
may be a prolonged interval between exposure or onset of hepatitis and antibody seroconversion. 
Persons negative for anti-HCV during their acute illness should be retested at least 3-4 months 
later to make a final diagnosis. Patients with a diagnosis of non-A, non-B hepatitis who remain 
negative for anti-HCV may have hepatitis C but fail to elicit an immune response detectable by the 
current assay, they may be infected with a second agent of non-A, non-B hepatitis, or their 
hepatitis may have another cause (viral or nonviral). Thus, the diagnosis of acute non-A, non-B 
hepatitis must continue to rely on the exclusion of other etiologies of liver disease even with the 
availability of a licensed test for anti-HCV. 
Historically, it was recommended that patients be tested monthly for alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) to detect possible non-A, non-B 
hepatitis infections, particularly occurring in clusters, that might indicate a problem with infection 
control practices. Isolation of dialysis patients with presumed non-A, non-B hepatitis in separate 
rooms on dedicated machines was not considered necessary or recommended; instead, the use of 
basic barrier precautions or what are now called universal precautions was emphasized. The 
availability of a commercial test for anti-HCV does not change these recommendations for the 
control of non-A, non-B hepatitis in the dialysis center. 
1.	 Dialysis unit precautions as outlined in Appendix II should be used for all patients. 
2.	 Patients who are positive for anti-HCV or have a diagnosis of non-A, non-B 
hepatitis do not have to be isolated from other patients or dialyzed separately on 
dedicated machines. In addition, they can participate in dialyzer reuse programs. 
3.	 Patients should be monitored for elevations in ALT and AST monthly. Elevations 
in liver enzymes currently are more sensitive indicators of acute hepatitis C than 
anti-HCV. 
4.	 Routine screening of patients or staff for anti-HCV is not necessary for purposes 
of infection control. Dialysis centers may wish to conduct serologic surveys of 
their patient populations to determine the prevalence of the virus in their center, 
and in the case of patients or staff with a diagnosis of non-A, non-B hepatitis, to 
determine medical management. In addition, if liver enzyme screening indicates 
the occurrence of an epidemic of non-A, non-B hepatitis in the dialysis setting, 
anti-HCV screening on serum samples collected during and subsequent to 
outbreaks may be of value. However, since anti-HCV in an individual cannot 





Voluntary Surveillance for Bloodstream and Vascular Access Infections 

in Outpatient Hemodialysis Centers
 
Bloodstream and vascular access infections are a threat to hemodialysis patients. Because 
of frequent hospitalizations and receipt of antimicrobials, drug-resistance is a particular problem in 
this population. However, there are few studies of rates of bacterial infections and antimicrobial 
resistance in hemodialysis patients, and there are no standardized methods for ongoing data 
collection. 
Therefore, CDC has created a national surveillance system to study these issues. 
Participation in this project is voluntary–dialysis center personnel decide whether to participate, 
and may elect to discontinue participation at any time. 
Each month, participating dialysis center personnel will record the number of chronic 
hemodialysis patients $18 years old that they treat (broken down into four types of vascular 
access). A one-page form will be completed for each hospitalization or in-unit intravenous (IV) 
antimicrobial start among these patients. These data will allow calculation, stratified by type of 
vascular access, of rates of bloodstream infections, vascular access infections, hospitalizations, 
and antimicrobial use. 
For individual dialysis centers, this surveillance system will provide a simple and 
standardized method to record data, calculate rates, and compare rates over time. It is hoped that 
collection and examination of these data will lead to quality improvement measures. For the 
medical and public health communities, aggregation of these data from many dialysis centers will 
provide a wealth of information which is not currently available. 
We anticipate that this system will be available in March 1999. A protocol describing the 
system, and information for enrolling, can be received by contacting: 
Elaine Miller, RN, MPH 
Centers for Disease Control and Prevention 
1600 Clifton Rd MS E-69 
Atlanta GA 30333 
fax 404-639-6459 
phone 404-639-6413 
email erm4@cdc.gov 
